Table 2.
Characteristics of 26 included studies (SR-cGVHD)*.
| Studies | Median age/year (range) | HLA matching (n) | SR-cGVHD grade (n) | Median time from SR-cGVHD diagnosis to the application of ruxolitinib/day (range) | |||||
|---|---|---|---|---|---|---|---|---|---|
| MRD | mMRD | MUD | mMUD | Mild | Moderate | Severe | |||
| Lancman, 2018 | 52 (38–71) | NA | NA | NA | NA | NA | NA | NA | NA |
| Hurabielle, 2017 | 47 (21–67) | 4 | NA | 8 | NA | NA | NA | NA | NA |
| Maas-Bauer, 2020 | 49 (28–70) | NA | NA | NA | NA | NA | NA | 13 | NA |
| Zeiser, 2022 | 49 (13–73) | 91 | NA | 76 | NA | 1 | 67 | 97 | NA |
| Ferreira, 2021 | 54 (23–73) | 18 | NA | 8 | NA | 0 | 23 | 12 | 510 (30–2130) |
| Ferreira, 2018 | 46.5 (23–68) | 10 | NA | NA | NA | 0 | 11 | 9 | 480 |
| Wei, 2021 | 31 (11–54) | 19 | NA | 1 | NA | 2 | 10 | 20 | 17 (7–1239) |
| Wang, 2021 | 35 (13–63) | 27 | NA | 2 | 41 | 23 | 38 | 9 | NA |
| Leung, 2022 | 33 (21–64) | NA | NA | NA | NA | 7 | 15 | 7 | NA |
| Moiseev, 2020 | 21 (2–62) | 7 | NA | 30 | NA | 0 | 6 | 37 | 376 (28–3219) |
| González, 2018 | 11 (5–18) | NA | NA | NA | NA | 1 | 1 | 7 | 540 |
| Kaurinovic, 2022 | 60 (26–76) | NA | NA | NA | NA | 10 | 35 | 8 | NA |
| Maldonado, 2017 | 36 (26–52) | 1 | NA | 2 | NA | NA | 1 | 4 | 180 (90–540) |
| Maldonado, 2021 | 38.5 (22–59) | NA | NA | NA | NA | 2 | 1 | 5 | NA |
| Schoettler, 2019 | 10 (7–21) | NA | NA | 5 | NA | NA | 1 | 4 | 120 (75–720) |
| Modi, 2018 | 49 (21–77) | 15 | NA | 10 | 16 | 3 | 8 | 35 | NA |
| Mozo, 2021 | 12 (2.1–16) | 1 | NA | 8 | NA | NA | 8 | 4 | NA |
| Zeiser, 2015 | 55 (22–74) | 9 | NA | 17 | NA | NA | 6 | 35 | NA |
| Abedin, 2019 | 59 (45–70) | 11 | 1 | 12 | 0 | NA | 16 | 8 | NA |
| Redondo, 2022 | 49 (18–72) | 27 | NA | 19 | 2 | 1 | 29 | 18 | 150 (18–630) |
| Dang, 2020 | 30 (14–55) | 15 | 8 | 5 | NA | NA | 24 | NA | NA |
| Uygun, 2020 | NA | NA | NA | NA | NA | NA | 2 | 13 | 840 (210–1560) |
| Gómez, 2019 | NA | NA | NA | NA | NA | 0 | 28 | 28 | NA |
| Wu, 2021 | 31 (17–56) | 9 | NA | NA | NA | NA | 14 | 27 | 330 (18–2,157) |
| Xue, 2021 | 45 (19–71) | 10 | 14 | 12 | NA | NA | 9 | 27 | 654 (69–4,482) |
| Zhao,2021 | 27 (15–54) | 8 | 21 | 1 | NA | NA | 6 | 24 | 125 (27–1,598) |
HLA, human leukocyte antigen; mMRD, mismatched related donor; MRD, matched related donor; mMUD, mismatched unrelated donor; MUD, matched unrelated donor; NA, not available; SR-cGVHD, steroid-refractory chronic graft-versus-host disease. *Thirteen studies included both SR-aGVHD and SR-cGVHD analysis.